HB Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$36M Buy
142,911
+1,807
+1% +$389K 0.2% 63
2026
Q1
$30.7M Buy
141,104
+6,079
+5% +$1.35M 0.2% 65
2025
Q4
$30.9M Buy
135,025
+8,453
+7% +$1.93M 0.2% 64
2025
Q3
$29.3M Buy
126,572
+10,420
+9% +$2.12M 0.2% 66
2025
Q2
$21.6M Sell
116,152
-10,632
-8% -$1.98M 0.17% 73
2025
Q1
$26.6M Buy
126,784
+18,846
+17% +$3.66M 0.22% 66
2024
Q4
$19.2M Buy
107,938
+12,036
+13% +$2.21M 0.2% 53
2024
Q3
$18.9M Buy
95,902
+2,119
+2% +$395K 0.2% 54
2024
Q2
$16.1M Buy
93,783
+5,534
+6% +$917K 0.19% 57
2024
Q1
$16.1M Sell
88,249
-4,990
-5% -$860K 0.2% 58
2023
Q4
$14.4M Buy
93,239
+1,619
+2% +$236K 0.21% 56
2023
Q3
$13.7M Buy
91,620
+4,327
+5% +$635K 0.22% 52
2023
Q2
$11.8M Sell
87,293
-2,071
-2% -$304K 0.19% 60
2023
Q1
$14.2M Buy
89,364
+2,641
+3% +$404K 0.25% 45
2022
Q4
$14M Buy
86,723
+9,731
+13% +$1.49M 0.26% 48
2022
Q3
$10.3M Buy
76,992
+13,494
+21% +$1.94M 0.22% 52
2022
Q2
$9.72M Buy
63,498
+18,353
+41% +$2.8M 0.2% 51
2022
Q1
$7.32M Buy
45,145
+5,119
+13% +$744K 0.14% 82
2021
Q4
$5.42M Buy
+40,026
New +$4.73M 0.11% 77

Other funds holding ABBV

HB Wealth Management's ABBV Position: Q2 2026 in Review

HB Wealth Management increased its AbbVie (ABBV) stake by 1.3% in Q2 2026, buying an estimated $389K and bringing the position to 142,911 shares worth $36M. The position accounts for 0.2% of the portfolio, ranked #63.

HB Wealth Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • HB Wealth Management held 142,911 shares of AbbVie worth $36M as of Q2 2026.
  • HB Wealth Management bought 1,807 AbbVie shares in Q2 2026, an estimated $389K.
  • AbbVie made up 0.2% of HB Wealth Management's portfolio in Q2 2026, its #63 holding.
  • HB Wealth Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.